Fulgent Genetics Inc. Common Stock (FLGT)

FairStock Score: 43/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business and the numbers. Fulgent sells diagnostic and genetic testing, a useful service but a competitive field where a durable moat is not obvious from the financials. In fiscal year 2025, the year ended 2025-12-31, revenue was $322.7 million, up from $283.5 million in fiscal year 2024, the year ended 2024-12-31, yet the net loss widened to $60.5 million from $42.7 million. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $85.4 million and net income was -$29.5 million; fiscal Q1 2026, the quarter ended 2026-03-31, produced $71.1 million of revenue and a -$24.8 million net loss. Those are not the marks of a healthy business. FairStock's numbers at the 2026-10-13 close of $21.06 show a negative P/E of -7.44, ROE of -8.11%, and ROCE of -6.30%. Free cash flow is deeply negative at -$103.8 million trailing twelve months, a -17.9% FCF yield. The balance sheet is a bright spot: debt to equity is 0.01, Altman Z-score is 4.74, and price-to-book is 0.58. But a low price-to-book can be a value trap if assets are consumed by losses. The Lynch category is TURNAROUND, based on a loss in the latest year after earlier profits. I would need evidence that expenses are being cut, revenue is growing, and cash burn is shrinking before calling this cheap. At a $579.5 million market cap, the market is pricing doubt, and the burden of proof is on the company.

In plain English: Fulgent Genetics provides clinical and genetic lab tests and related services. The business looks weak right now because it lost money in its latest quarter and is using more cash than it brings in. The stock price may look low compared with the value of its assets, but the losses make it a risky and uncertain situation.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer